Evidence map›Paper›PMID 39411667›Full record

ArticleAntimicrobial stewardship & healthcare epidemiology : ASHE2024

Informing estimates of probability of

Jonathan D Baghdadi, Mia Wessel, Erik R Dubberke, Alison Lydecker, Kimberly C Claeys, Carolyn Alonso, K C Coffey, Michael Durkin, Anne J Gonzales-Luna, Alice Y Guh and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial stewardship & healthcare epidemiology : ASHE, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jonathan D BaghdadiUniversity of Maryland, Baltimore, Baltimore, MD, USA.ORCID https://orcid.org/0000-0002-2442-0654
Mia WesselUniversity of Maryland, Baltimore, Baltimore, MD, USA.
Erik R DubberkeWashington University School of Medicine, St. Louis, MO, USA.ORCID https://orcid.org/0000-0003-3779-2796
Alison LydeckerUniversity of Maryland, Baltimore, Baltimore, MD, USA.
Kimberly C ClaeysUniversity of Maryland, Baltimore, Baltimore, MD, USA.ORCID https://orcid.org/0000-0001-6895-604X
Carolyn AlonsoBeth Israel Deaconess Medical Center, Boston, MA, USA.
K C CoffeyUniversity of Maryland, Baltimore, Baltimore, MD, USA.ORCID https://orcid.org/0009-0003-1548-7202
Michael DurkinWashington University School of Medicine, St. Louis, MO, USA.ORCID https://orcid.org/0000-0003-4652-7089
Anne J Gonzales-LunaUniversity of Houston College of Pharmacy, Houston, TX, USA.ORCID https://orcid.org/0000-0003-1906-359X
Alice Y GuhCenters for Disease Control and Prevention, Atlanta, GA, USA.
Jennie H KwonWashington University School of Medicine, St. Louis, MO, USA.ORCID https://orcid.org/0009-0007-9774-6835
Elise MartinUniversity of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID https://orcid.org/0000-0001-5106-1864
Preeti MehrotraBeth Israel Deaconess Medical Center, Boston, MA, USA.ORCID https://orcid.org/0000-0002-3192-5466
Christopher R PolageDuke University School of Medicine, Durham, NC, USA.ORCID https://orcid.org/0000-0003-1433-6886
Michael S PuliaUniversity of Wisconsin School of Medicine and Public Health, Madison, WI, USA.ORCID https://orcid.org/0000-0001-5809-4060
Clare RockJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Andrew M SkinnerUniversity of Utah School of Medicine, Salt Lake City, UT, USA.ORCID https://orcid.org/0000-0001-9452-9316
Valerie M VaughnUniversity of Utah School of Medicine, Salt Lake City, UT, USA.
Tara VijayanUCLA School of Medicine, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0003-1141-8261
Michael E YarringtonDuke University School of Medicine, Durham, NC, USA.ORCID https://orcid.org/0000-0003-3186-1519
Daniel J MorganUniversity of Maryland, Baltimore, Baltimore, MD, USA.
CDC Prevention Epicenters Program

Funding

AHRQ HHS K08 HS028854BLRD VA IK2 BX005609
6 · The paper itself

Abstract

Background: Methods: A panel of fifteen experts in infectious diseases participated in a modified UCLA/RAND Delphi study to estimate likelihood of CDI. Consensus, defined as agreement by >70% of panelists, was assessed via a REDCap survey. Items without consensus were discussed in a virtual meeting followed by a second survey. Results: All fifteen panelists completed both surveys (100% response rate). In the initial survey, consensus was present on 6 of 15 (40%) items related to risk of CDI. After panel discussion and clarification of questions, consensus (>70% agreement) was reached on all remaining items in the second survey. Antibiotics were identified as the primary risk factor for CDI and grouped into three categories: high-risk (likelihood ratio [LR] 7, 93% agreement among panelists in first survey), low-risk (LR 3, 87% agreement in first survey), and minimal-risk (LR 1, 71% agreement in first survey). Other major factors included new or unexplained severe diarrhea (e.g., ≥ 10 liquid bowel movements per day; LR 5, 100% agreement in second survey) and severe immunosuppression (LR 5, 87% agreement in second survey). Conclusion: Infectious disease experts concurred on the importance of signs, symptoms, and healthcare exposures for diagnosing CDI. The resulting risk estimates can be used by clinicians to optimize CDI testing and treatment.

Identifiers

PMID39411667
PMCPMC11474763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.